<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526968</url>
  </required_header>
  <id_info>
    <org_study_id>EVT 101/1002</org_study_id>
    <secondary_id>EudraCT No.: 2007-000986-40</secondary_id>
    <nct_id>NCT00526968</nct_id>
  </id_info>
  <brief_title>The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function</brief_title>
  <official_title>A Double Blind, Placebo Controlled Study to Investigate the Role of NMDA Receptor NR2B Subunit Selective Antagonism on Cognitive Functions and Neurophysiology in Healthy Subjects as Measured With MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evotec Neurosciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Richmond Pharmacology Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Evotec Neurosciences GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the neurophysiological changes following single
      doses of EVT 101 using fMRI during rest and during cognitive tasks in young healthy male
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fMRI BOLD signal under baseline conditions and during activation by cognitive tasks</measure>
    <time_frame>2-hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in regional cerebral blood flow (determined with ASL-MRI)after drug compared with placebo</measure>
    <time_frame>2-hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance scores in the cognitive tests</measure>
    <time_frame>2-hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, tolerability, adverse events, safety laboratory tests, ECG, vital signs</measure>
    <time_frame>Up to 24 hours post dose and 5-7 days post last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Human Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVT 101 8 mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVT 101 15 mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVT 101</intervention_name>
    <description>8 mg capsule, single oral dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVT 101</intervention_name>
    <description>15 mg capsule, single oral dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo capsule, single oral dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Male volunteers

          -  Body Mass Index between 19 and 29

        Exclusion Criteria:

          -  Subjects who received any prescribed medication within 5 half lives or 14 days of the
             first dose administration whichever is the longer

          -  Subjects who have received any prescribed CNS medication or any medication known to
             chronically alter drug absorption or elimination processes within 30 days of first
             dose administration

          -  Participation in a clinical trial of an investigational drug within the past 4 months
             or of a marketed drug within the past 3 months

          -  History of allergy to NMDA antagonists or other clinically significant drug allergy

          -  Supine blood pressure and heart rate of higher than 140/90 mmHg and 90 bpm
             respectively or lower than 80/40 mmHg and 40 bpm

          -  Consumption of more than 21 units of alcohol per week or history of alcoholism or
             drug/chemical abuse

          -  Smokers of more than 5 cigarettes or equivalent per day

          -  Subjects who cannot complete the neuropsychological test battery

          -  Any clinically significant health deficit
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Leigh, BSc MBBS Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Neurosciences, Institute of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Neuroimaging Science, Box 089, Institute of Psychiatry</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2007</study_first_submitted>
  <study_first_submitted_qc>September 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>February 14, 2008</last_update_submitted>
  <last_update_submitted_qc>February 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Hermann Fuder, Senior VP, Clinical Development</name_title>
    <organization>Evotec Neurosciences GmbH</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

